L. Gervitz

A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol

J. Curtis, A. Kivitz, J. Melin, 2015, Arthritis & rheumatology.

Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial

D. M. van der Heijde, R. Landewé, D. Furst, 2012, The Journal of Rheumatology.

Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.

N. Goel, J. Curtis, M. Weinblatt, 2011, Arthritis and rheumatism.

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

G. Burmester, J. Smolen, B. Haraoui, 2016, The Lancet.

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension

V. Strand, M. Genovese, K. Thangavelu, 2019, RMD Open.

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

G. Burmester, J. Smolen, B. Haraoui, 2016, The Lancet.